← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biomarker Strategies, Llc
Derwood, MD
$8,298,016
Total funding
7
Grants
Funding over time
peak $1.5M · FY2009–19$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,298,016 · 7
By mechanism
N44$2,996,596 · 2
N43$2,720,031 · 3
R44$2,282,049 · 1
R43$299,340 · 1
Investigators at Biomarker Strategies, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Functional Companion Diagnostic Test to Predict Optimal Therapy for Melanoma$1,498,569
N44 · FY2013 · CA
SBIR Topic 354: A Novel Predictive Test for Response to Combination Immunotherapies for Patients with non-small cell lung cancer (NSCLC)$1,498,027
N44 · FY2019 · CA
SBIR TOPIC 257, INSTRUMENTS AND DEVICES THAT PRESERVE MOLECULAR PROFILES IN TUMO$1,037,959
N43 · FY2011 · CA
SBIR TOPIC 257, INSTRUMENTS AND DEVICES THAT PRESERVE MOLECULAR PROFILES IN TUMO$1,011,413
N43 · FY2010 · CA
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$993,966
R44 · FY2018 · CA
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$988,207
R44 · FY2017 · CA
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$299,876
R44 · FY2015 · CA
Development of a companion diagnostic to predict response to cetuximab in patients with head and neck squamous cell carcinoma$299,340
R43 · FY2017 · CA
SBIR TOPIC 257, INSTRUMENTS AND DEVICES THAT PRESERVE MOLECULAR PROFILES IN TUMO$254,810
N43 · FY2009 · CA
IGF::OT::IGF SBIR PHASE I TOPIC 354-A NOVEL PREDICTIVE TEST FOR RESPONSE TO IMMUNOTHERAPIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER; POP 09/19/16-06/18/17$223,063
N43 · FY2016 · CA
TAS::75 0849::TAS SBIR TOPIC 277 - PHASE I SNAPMAPTM: A FUNCTIONAL COMPANION DIA$192,786
N43 · FY2011 · CA